Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Growth Hormone Releasing Peptide-2
Also known as: Pralmorelin, KP-102, D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2
Confidence
Updated 2026-03-18
GHRP-2 is a synthetic hexapeptide GH secretagogue considered the most potent GHRP in terms of GH release per dose. It is approved in Japan as a diagnostic agent for GH deficiency (under the name Pralmorelin). It provides a strong GH stimulus with moderate appetite effects — positioned between the hunger-inducing GHRP-6 and the clean-profile ipamorelin.
Class
GH Secretagogue (GHRP)
Routes
Subcutaneous, Intravenous, Intranasal
Half-Life
~25–30 minutes
GHRP-2 activates the GHS-R1a receptor on pituitary somatotrophs, stimulating GH release. It also acts at the hypothalamic level to stimulate GHRH release and suppress somatostatin. Produces the highest amplitude GH pulse among GHRPs. Moderate ghrelin-like appetite effects (less than GHRP-6). Mild cortisol and prolactin elevation at therapeutic doses.
Half-Life
~25–30 minutes
Bioavailability
Subcutaneous: ~60–70% (estimated)
Approved (Japan only): Diagnostic assessment of GH deficiency. Research: GH optimization, body composition, anti-aging protocols, sleep quality.
Well-studied in Japanese clinical trials as a GH deficiency diagnostic. Produces the largest GH response among GHRPs in head-to-head comparisons. Multiple short-term human PK/PD studies. Limited long-term therapeutic data. Japanese regulatory approval provides a degree of clinical validation for acute use.
Human Studies
20
Animal Studies
45
Generally well-tolerated for acute diagnostic use. Moderate appetite stimulation. Transient cortisol and prolactin elevation. Water retention. May worsen insulin resistance with chronic use. Desensitization can occur with prolonged use.
Approved in Japan for GH deficiency diagnosis. Not FDA-approved. WADA-prohibited. Available as a research peptide internationally.
Drug Interactions: Caution with corticosteroids, diabetes medications. May potentiate effects of GHRH analogs synergistically. Monitoring: GH, IGF-1, cortisol, prolactin, fasting glucose. Research Gaps: No large Western therapeutic trials. Chronic use safety profile not established.
Subcutaneous (research context)
Common Range
100–300 mcg/dose
Timing
Fasted state, morning or pre-bedtime
Frequency
1–3 times daily
Cycling
4–12 weeks on, 4 weeks off
Reconstitution
Reconstitute lyophilized powder with bacteriostatic water
Storage
Refrigerated after reconstitution
Important Note
NOT FDA-approved. Most potent GHRP for GH release. Often combined with CJC-1295 for synergistic effect.
Connect with a verified provider offering GHRP-2 therapy near you.
GH Secretagogue (GHRP)
GHRP-6 is a synthetic hexapeptide that potently stimulates growth hormone release via the ghrelin receptor. It was one of the earliest GHRPs discovered and is notable for its strong appetite-stimulating effects (mediated by ghrelin pathway activation). It has been widely used in research settings for GH axis assessment and body composition studies.
GH Secretagogue
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to stimulate GH release from the pituitary. It is considered one of the most selective GH secretagogues, with minimal effect on cortisol, prolactin, and other hormones — making it a preferred choice in combination protocols with CJC-1295.
GH Secretagogue (GHRP)
Hexarelin is a synthetic hexapeptide growth hormone secretagogue and one of the most potent GHRPs studied. It stimulates GH release via the ghrelin receptor and has unique cardioprotective properties independent of its GH-releasing activity. Despite promising research, it was never brought to market due to tachyphylaxis (reduced response with repeated dosing).
GH Secretagogue
CJC-1295 is a synthetic analog of GHRH(1-29) with modifications to extend its half-life. Available in two forms: with Drug Affinity Complex (DAC) for prolonged action, and without DAC (also called Modified GRF 1-29) for shorter, more pulsatile action. Frequently combined with ipamorelin for synergistic GH release.
GHRH Analog
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. Originally FDA-approved for diagnostic use in assessing growth hormone secretion, it has become a cornerstone of legitimate peptide therapy for growth hormone optimization due to its established safety profile and compounding eligibility.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.